BioElectronics Corp Surges on FDA Clearance for RecoveryRx(R)

0
805

BioElectronics Corp. has seen a massive surge in trading volume after the Company announced it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx(R) medical device, for the treatment of postoperative pain. BIEL is a very liquid stock with a large investors base that has been a staple among the top most traded stocks on the OTC over the past year.

The Company operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use.

BioElectronics Corp is focused on becoming a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. BIEL innovative pulsed shortwave therapy technology (PSWT) uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

BIEL OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for the company’s flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. The Company is aggressively pursuing US FDA over-the-counter market clearance to access the United States market.

For the inside scoop on BIEL enter your email address below

Sign Up now for our 100% FREE Penny Stock Newsletter

BIEL is already booking revenues reporting $144k in revenues for the 3 months ended March 29, 2019; In February 2017, BIEL announced that it received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.

On July 1 BIEL announced it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx(R) medical device, for the treatment of postoperative pain. Physicians are discarding opioid-centric pain management, instead focusing on a multimodal approach of two or more analgesic therapies to decrease the use of opioids and to achieve more effective pain control [1]. Currently, less than 50% of patients who undergo surgery report adequate postoperative pain relief [2]. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.

RecoveryRx is a superior, drug-free, safe therapy and will be available to the 15 million Americans who experience postoperative pain from 25 million surgeries, annually [3]. Additionally, debridement and negative vac therapy treatments among the 7 million chronic wound patients are a significant market opportunity for RecoveryRx therapy.

Andrew Whelan, President, expressed confidence in seizing the market opportunity:

“We are delighted that the FDA has recognized the potential of RecoveryRx in transforming postoperative pain care. RecoveryRx, with its high degree of safety, excellent clinical evidence of effectiveness and exceptional cost-benefit, will become the standard of care.”

Currently trading at a $15 million market valuation BIEL has little cash on hand with over $6 million in current liabilities and revenues of $144k for the 3 months ended March 29, 2019; BIEL is an exciting story in small caps; the Company is already selling its flagship, the ActiPatch which addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. BIEL just received market clearance from the FDA for its RecoveryRx(R) medical device which could be a disrupter in a billion-dollar market. There is huge demand for BIEL here, more than most penny stocks could dream of, if they can reach an agreement with debt holders big things could happen here. We will be updating on BIEL when more details emerge so make sure you are subscribed to NewsyTrends so you know what’s going on with BIEL.

For the inside scoop on BIEL enter your email address below

Sign Up now for our 100% FREE Penny Stock Newsletter

LEAVE A REPLY

Please enter your comment!
Please enter your name here